The strong growth in sleep therapy patients (62% YoY) and robust 2026 guidance suggest continued momentum. The share repurchase program indicates confidence in future cash flows. Monitor Q1 2026 results to confirm if growth trajectory continues.
Price Chart
Executive Summary
Viemed Healthcare reported record 2025 financial results with 21% revenue growth to $270.3 million and 33% net income growth to $14.9 million. The company also announced a new $26.3 million share repurchase program and provided 2026 guidance projecting revenue of $310-320 million and Adjusted EBITDA of $65-69 million.
Key Financial Metrics
Key Facts
- Record 2025 revenue of $270.3 million (21% YoY growth)
- Net income of $14.9 million (33% YoY growth)
- PAP therapy patient count increased 62% YoY to 34,528
- Sleep resupply patient count increased 49% YoY to 36,561
- 2026 guidance: $310-320 million revenue, $65-69 million Adjusted EBITDA
- New $26.3 million share repurchase program authorized
Financial Impact
$26.3 million share repurchase program announced; 2026 revenue guidance of $310-320 million (15-18% growth)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Ventilator rentals | $136.7M | +9.8% |
| PAP therapy | $50.3M | +62.7% |
Risk Factors
- Guidance excludes potential acquisitions which could impact results
- Dependence on key suppliers and reimbursement rates from payors
- Competition in the home healthcare market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001729149-26-000008 |
| Exhibit: ex99303042026.htm | 0001729149-26-000008 |
| Document: vmd-20260304.htm | 0001729149-26-000008 |
| Document: viemed_q42025supplementa.htm | 0001729149-26-000008 |
| Document: 0001729149-26-000008-index-headers.html | 0001729149-26-000008 |
| Document: 0001729149-26-000008-index.html | 0001729149-26-000008 |
| Document: 0001729149-26-000008.txt | 0001729149-26-000008 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 24, 2026 4w ago | SC 13D/A | $8.91 $9.11 | ▼ −2.24% | ▼ −2.99% | $9.73 (−9.20%) |
Aug 20, 2026 9w ago | 8-K | $8.85 $9.09 | ▲ +2.71% | ▲ +3.01% | $9.73 (+9.94%) |
Aug 3, 2026 11w ago | 8-K | $9.84 $9.82 | ▼ −0.15% | ▲ +0.05% | $9.73 (−1.07%) |
Jun 4, 2026 20w ago | 8-K | $9.97 $9.92 | ▼ −0.50% | ▼ −0.73% | $9.73 (−2.41%) |
Jun 2, 2026 20w ago | 8-K | $9.56 $9.84 | ▲ +2.93% | ▲ +2.53% | $9.73 (+1.78%) |
May 5, 2026 24w ago | 8-K | $8.52 $8.52 | · 0.00% | ▲ +0.33% | $9.73 (+14.27%) |
Mar 4, 2026 33w ago | 8-K | $8.40 $8.78 | ▲ +4.52% | ▲ +5.84% | $9.73 (+15.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers